BioSpace News Archive

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, revealed the speaker line-up for Breakthrough 2024, its annual industry event.

Polpharma Biologics announced topline results demonstrating the pharmacokinetic and pharmacodynamics comparability of its biosimilar candidate PB016 to its reference drug, Entyvio®*.

Zylox-Tonbridge, a medical device company specializing in peripheral and neurovascular interventions, proudly announces the recent marketing approvals granted by the Ministry of Health and Prevention in the United Arab Emirates for five of its advanced products.

Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON) today announced that the United States Patent and Trademark Office (“USPTO”) has granted the Company’s U.S. Patent Application No. 18/113,458, which covers the Company’s ET-400 product candidate’s proprietary formulation of oral liquid hydrocortisone.

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 114.2 million in the fourth quarter of 2023, an increase of 20% over the prior-year period, and EBITDA of NOK 29.9 million following solid business development for the Company.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.

PolTREG S.A. announces it has appointed Prof. Daniel Shelly, PhD, MBA, into the role of Chief Business Development Officer, to help PolTREG build the strategic, commercial, research and pharmaceutical partnerships that will enable the company to successfully commercialise its strong pipeline of cell therapies for diseases such as Type-1 Diabetes, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

Genezen announced licensing of the Cytegrity™ proprietary stable production system from biotechnology leader CSL.

Aleta Biotherapeutics, a clinical stage, immuno-oncology company with a CAR T-Cell Engager platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, announce the first patient was dosed in a Phase 1/2 clinical trial.

LivaNova PLC, a market-leading medical technology company, reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024.